Revive Therapeutics Ltd
Change company Symbol lookup
Select an option...
RVVTF Revive Therapeutics Ltd
JPM-K JPMorgan Chase & Co
MAX Mediaalpha Inc
BB BlackBerry Ltd
MORN Morningstar Inc
GHYUSiv.P JPM Gbl HY Corpo Bd Multi-Fctr UCITS ETF USD A
DBD Diebold Nixdorf Inc
SHPH Shuttle Pharmaceuticals Holdings Inc
MSGE Madison Square Garden Entertainment Corp
IMMX Immix Biopharma Inc
Go

Health Care : Pharmaceuticals | Small Cap Value
Based in Canada

Revive Therapeutics Ltd. is a Canada-based life sciences company. The Company is focused on the research and development of therapeutics for rare disorders and infectious diseases. The Company is exploring the use of Bucillamine for the treatment of infectious diseases, with an initial focus on severe influenza and COVID-19. Through its subsidiary, Psilocin Pharma Corp., the Company is advancing the development of Psilocybin-based therapeutics in various diseases and disorders. The Company’s cannabinoid pharmaceutical portfolio focuses on rare inflammatory diseases and the Company was granted Food and Drug Administration (FDA) orphan drug status designation for the use of Cannabidiol (CBD) to treat autoimmune hepatitis (liver disease) and to treat ischemia and reperfusion injury from organ transplantation.

Closing Price: $0.0475

Day's Change: 0.00 (0.00%)

Bid: --

Ask: --

B/A Size: --

Day's High: --

Day's Low: --

Volume (Light) Volume: 178,261 10-day average volume: 496,701: 178,261

Market data accompanied by is delayed by at least 15 minutes for NASDAQ, NYSE MKT, NYSE, and options. Duration of the delay for varies.

Market data and information provided by Morningstar.

The risk of loss in trading futures can be substantial. Clients must consider all relevant risk factors, including their own personal financial situation, before trading. Margin and level 2 options approval or higher is required. Not all account owners will qualify.

Dividends are converted to USD using the current rate of exchange at the end of the business day on the day the dividend went EX. Earnings are converted to USD using the current rate of exchange at the end of the business day on the day earnings were announced.

Reuters content is the intellectual property of Reuters. Any copying, republication or redistribution of Reuters content, including by caching, framing or similar means, is expressly prohibited without the prior written consent of Reuters. Reuters is not liable for any errors or delays in content, or for any actions taken in reliance on any content. Reuters, Reuters Logo and the Sphere Logo are trademarks and registered trademarks of the Reuters Group of companies around the world.

Data is provided for information purposes only and is not intended for trading purposes. Reuters shall not be liable for any errors or delay in the content, or for any action taken in reliance on any content. The RIC or Reuters Instrument Code set has been developed and maintained by Reuters and is the intellectual property of Reuters.